Enzo Biochem Concludes Transition to Private Ownership

The biotechnology firm Enzo Biochem has completed its departure from public markets. The company’s shares have been delisted following its acquisition, concluding its lengthy tenure as a publicly traded entity. Shareholders have received their cash settlements, formally ending this chapter for investors.

A Strategic Acquisition and Delisting Process

The path to privatization was finalized through a merger with Bethpage Parent on August 20 of last year. This transaction represented the culmination of a broader strategic shift. Prior to the merger, Enzo Biochem had voluntarily terminated its listing on the New York Stock Exchange (NYSE) in April 2025, subsequently trading on the OTCQX market for an interim period.

As part of the merger agreement, all outstanding common shares were converted into cash payments. This action terminated all public trading activity for the stock. The company now operates as a privately held subsidiary, free from the continuous reporting obligations and market scrutiny faced by public companies.

Should investors sell immediately? Or is it worth buying Enzo Biochem?

Legal Matters Resolved and Future Path

In preparation for going private, Enzo Biochem addressed several outstanding legal issues. Notably, the company settled matters related to past data security incidents. These legal affairs are now consigned to the company’s history as its operational business reorganizes under private management.

With the delisting complete, Enzo Biochem will no longer issue quarterly earnings reports or hold public shareholder meetings. Former investors have received their cash payouts as stipulated in the acquisition terms, finalizing their investment. Moving forward, the company will pursue its diagnostics development agenda under its new ownership structure, without the disclosure requirements of the public capital markets.